Astellas Pharma Inc. (4503.T) Financial Statements

Income statement

Metric	TTM	2026	2025	2024	2023
Revenue
Total Revenue	2139.2B	2139.2B	1912.3B	1603.7B	1518.6B
Cost of Revenue	94.8B	408.4B	349.2B	292.5B	288.4B
Gross Profit	411.0B	1730.8B	1563.1B	1311.2B	1230.3B
Operating Expenses
R&D Expense	—	—	—	—	—
SG&A Expense	197.0B	860.3B	843.0B	740.1B	630.3B
General & Admin Expense	—	—	—	—	—
Selling & Marketing Expense	—	—	—	—	—
Other Expenses	21.3B	72.4B	235.8B	167.8B	157.5B
Total Operating Expenses	218.3B	932.8B	1078.8B	907.9B	787.8B
Cost and Expenses	1756.6B	1756.6B	1871.3B	1578.2B	1385.6B
Operating Income (EBIT)	382.6B	382.6B	41.0B	25.5B	133.0B
Non-Operating
Interest Income	1.7B	8.0B	7.9B	11.5B	8.1B
Interest Expense	5.9B	14.1B	17.7B	12.0B	8.8B
Net Interest Income	(4.2B)	(6.0B)	(9.8B)	(550.0M)	(669.0M)
Other Non-Op Income/Expense	4.4B	32.8B	20.3B	8.7B	3.6B
Non-Operating Income (excl Interest)	—	—	—	—	—
EBT (Pre-Tax Income)	90.4B	376.6B	31.2B	25.0B	132.4B
Income Tax Expense	22.0B	85.0B	(19.5B)	7.9B	33.6B
Bottom Line
Net Income	291.5B	291.5B	50.7B	17.0B	98.7B
Earnings from Cont. Ops	—	—	—	—	—
Earnings from Discont. Ops	—	—	—	—	—
Bottom Line Net Income	291.6B	291.6B	50.7B	17.0B	98.7B
Per Share
Basic EPS	¥163	¥163	¥28	¥10	¥54
Diluted EPS	¥163	¥163	¥28	¥9	¥54
Revenue Per Share	¥1,194	¥1,194	¥1,068	¥894	¥834
Shares
Basic Shares Outstanding	1.8B	1.8B	1.8B	1.8B	1.8B
Diluted Shares Outstanding	—	—	—	—	—
Profitability Metrics
EBITDA	—	—	—	—	—
D&A	—	—	—	—	—
EBIT	382.6B	382.6B	41.0B	25.5B	133.0B

As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Mar 1, 2026